Key Metrics
14.7
Heat Index-
Impact LevelMedium
-
Scope LevelNational
-
Last Update2025-09-08
Key Impacts
Positive Impacts (4)
Negative Impacts (3)
Event Overview
The development of a new mRNA-based cancer vaccine highlights advancements in biotechnology and immunotherapy. The vaccine, designed to trigger an immune response against cancer cells, has shown safety and efficacy in preclinical and clinical trials, representing a significant step in cancer treatment.
Collect Records
Russian Scientists Develop mRNA-Based Cancer Vaccine Enteromix
The Federal Medical and Biological Agency (FMBA) of Russia, led by Veronika Skvortsova, announced the development of a new mRNA-based cancer vaccine called Enteromix at the Eastern Economic Forum. The vaccine uses mRNA technology to instruct the body's cells to produce proteins that trigger an immune response against cancer cells. After years of research and three years of preclinical trials, the vaccine has proven to be safe and highly effective, even with repeated doses. Clinical trials showed that tumors shrank or grew more slowly by 60-80%, depending on the cancer type, and improved survival rates were observed. The vaccine is now ready for clinical use and will be provided free to patients. The initial focus will be on specific types of cancer.